Biotech · Public company · South San Francisco, CA, US

Tenaya Therapeutics, Inc.

Ticker TNYA · SEC CIK 0001858848

Track this companyFree. Adds Tenaya Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials44 recruiting or active

Pipeline programs2From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline2

TN-201Phase 2 · Hypertrophic CardiomyopathyClinicalTrials.gov · fetched Nov 12, 2026
TN-401Phase 1 · Arrhythmogenic Right Ventricular CardiomyopathyClinicalTrials.gov · fetched Nov 12, 2026

Open-label, Dose Escalation Study of Safety and Preliminary Efficacy of TN-401 in Adults With PKP2 Mutation-associated ARVCPHASE1 · RECRUITING · started Mar 26, 2024ClinicalTrials.gov NCT06228924 · fetched Nov 12, 2026
Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCMPHASE1_PHASE2 · RECRUITING · started Aug 10, 2023ClinicalTrials.gov NCT05836259 · fetched Nov 12, 2026
Non-interventional Study of Seroprevalence of Pre-existing Antibodies Against Adenovirus-associated Virus Vector (AAV9) and the Progression of Disease in Patients With Plakophilin 2 (PKP2)-Associated Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC)RECRUITING · started Jan 31, 2023ClinicalTrials.gov NCT06311708 · fetched Nov 12, 2026
Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated CardiomyopathyACTIVE_NOT_RECRUITING · started Nov 1, 2021ClinicalTrials.gov NCT05112237 · fetched Nov 12, 2026